vs
Prestige Consumer Healthcare Inc.（PBH）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ROYAL GOLD INC的季度营收约是Prestige Consumer Healthcare Inc.的1.3倍（$375.3M vs $283.4M），ROYAL GOLD INC净利率更高（24.9% vs 16.5%，领先8.5%），ROYAL GOLD INC同比增速更快（85.3% vs -2.4%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
PBH vs RGLD — 直观对比
营收规模更大
RGLD
是对方的1.3倍
$283.4M
营收增速更快
RGLD
高出87.7%
-2.4%
净利率更高
RGLD
高出8.5%
16.5%
两年增速更快
RGLD
近两年复合增速
1.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $375.3M |
| 净利润 | $46.7M | $93.6M |
| 毛利率 | 55.5% | 64.6% |
| 营业利润率 | 29.1% | 56.2% |
| 净利率 | 16.5% | 24.9% |
| 营收同比 | -2.4% | 85.3% |
| 净利润同比 | -23.5% | -12.8% |
| 每股收益（稀释后） | $0.97 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBHRGLD
| Q4 25 | $283.4M | $375.3M | ||
| Q3 25 | $274.1M | $252.1M | ||
| Q2 25 | $249.5M | $209.6M | ||
| Q1 25 | $296.5M | $193.4M | ||
| Q4 24 | $290.3M | $202.6M | ||
| Q3 24 | $283.8M | $193.8M | ||
| Q2 24 | $267.1M | $174.1M | ||
| Q1 24 | $277.0M | $148.9M |
净利润PBHRGLD
| Q4 25 | $46.7M | $93.6M | ||
| Q3 25 | $42.2M | $126.8M | ||
| Q2 25 | $47.5M | $132.3M | ||
| Q1 25 | $50.1M | $113.5M | ||
| Q4 24 | $61.0M | $107.4M | ||
| Q3 24 | $54.4M | $96.2M | ||
| Q2 24 | $49.1M | $81.2M | ||
| Q1 24 | $49.5M | $47.2M |
毛利率PBHRGLD
| Q4 25 | 55.5% | 64.6% | ||
| Q3 25 | 55.3% | 73.6% | ||
| Q2 25 | 56.2% | 72.6% | ||
| Q1 25 | 57.3% | 69.4% | ||
| Q4 24 | 55.5% | 70.3% | ||
| Q3 24 | 55.5% | 66.6% | ||
| Q2 24 | 54.7% | 64.7% | ||
| Q1 24 | 54.8% | 58.4% |
营业利润率PBHRGLD
| Q4 25 | 29.1% | 56.2% | ||
| Q3 25 | 29.1% | 64.4% | ||
| Q2 25 | 28.8% | 67.7% | ||
| Q1 25 | 29.8% | 63.6% | ||
| Q4 24 | 31.7% | 65.9% | ||
| Q3 24 | 29.7% | 61.3% | ||
| Q2 24 | 27.0% | 58.6% | ||
| Q1 24 | 29.7% | 50.7% |
净利率PBHRGLD
| Q4 25 | 16.5% | 24.9% | ||
| Q3 25 | 15.4% | 50.3% | ||
| Q2 25 | 19.0% | 63.1% | ||
| Q1 25 | 16.9% | 58.7% | ||
| Q4 24 | 21.0% | 53.0% | ||
| Q3 24 | 19.2% | 49.7% | ||
| Q2 24 | 18.4% | 46.6% | ||
| Q1 24 | 17.9% | 31.7% |
每股收益（稀释后）PBHRGLD
| Q4 25 | $0.97 | $1.04 | ||
| Q3 25 | $0.86 | $1.92 | ||
| Q2 25 | $0.95 | $2.01 | ||
| Q1 25 | $1.00 | $1.72 | ||
| Q4 24 | $1.22 | $1.63 | ||
| Q3 24 | $1.09 | $1.46 | ||
| Q2 24 | $0.98 | $1.23 | ||
| Q1 24 | $0.98 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $233.7M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $7.2B |
| 总资产 | $3.5B | $9.5B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
现金及短期投资PBHRGLD
| Q4 25 | $62.4M | $233.7M | ||
| Q3 25 | $119.1M | $172.8M | ||
| Q2 25 | $139.5M | $248.2M | ||
| Q1 25 | $97.9M | $240.8M | ||
| Q4 24 | $50.9M | $195.5M | ||
| Q3 24 | $51.5M | $127.9M | ||
| Q2 24 | $34.3M | $74.2M | ||
| Q1 24 | $46.5M | $137.9M |
总债务PBHRGLD
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | $0 | ||
| Q2 24 | $1.1B | $50.0M | ||
| Q1 24 | $1.1B | — |
股东权益PBHRGLD
| Q4 25 | $1.8B | $7.2B | ||
| Q3 25 | $1.8B | $3.4B | ||
| Q2 25 | $1.9B | $3.3B | ||
| Q1 25 | $1.8B | $3.2B | ||
| Q4 24 | $1.8B | $3.1B | ||
| Q3 24 | $1.7B | $3.0B | ||
| Q2 24 | $1.7B | $3.0B | ||
| Q1 24 | $1.7B | $2.9B |
总资产PBHRGLD
| Q4 25 | $3.5B | $9.5B | ||
| Q3 25 | $3.4B | $4.5B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $3.4B | $3.5B | ||
| Q4 24 | $3.3B | $3.4B | ||
| Q3 24 | $3.3B | $3.3B | ||
| Q2 24 | $3.3B | $3.3B | ||
| Q1 24 | $3.3B | $3.3B |
负债/权益比PBHRGLD
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.02× | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 1.68× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
经营现金流PBHRGLD
| Q4 25 | $78.3M | $241.7M | ||
| Q3 25 | $57.5M | $174.0M | ||
| Q2 25 | $79.0M | $152.8M | ||
| Q1 25 | $61.8M | $136.4M | ||
| Q4 24 | $65.1M | $141.1M | ||
| Q3 24 | $69.8M | $136.7M | ||
| Q2 24 | $54.8M | $113.5M | ||
| Q1 24 | $66.9M | $138.3M |
自由现金流PBHRGLD
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $63.8M | — |
自由现金流率PBHRGLD
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 23.0% | — |
资本支出强度PBHRGLD
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.1% | — |
现金转化率PBHRGLD
| Q4 25 | 1.68× | 2.58× | ||
| Q3 25 | 1.36× | 1.37× | ||
| Q2 25 | 1.66× | 1.15× | ||
| Q1 25 | 1.23× | 1.20× | ||
| Q4 24 | 1.07× | 1.31× | ||
| Q3 24 | 1.28× | 1.42× | ||
| Q2 24 | 1.12× | 1.40× | ||
| Q1 24 | 1.35× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
